This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oct. 23, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, will be presenting at the Singular Research seventh annual "Best of the Uncovereds" Conference on
Thursday, November 1st in
Management is scheduled to present at
3:00 p.m. PT (
6:00 p.m. EDT).
During the remainder of the day, Bacterin management will meet with investors during a series of one-on-one breakout meetings. Interested parties should contact
Bill Jones at Singular (267-987-2082) to schedule a meeting. The conference is being held at the Luxe Sunset Boulevard Hotel in
A live webcast of this presentation will be provided at:
About Singular ResearchSingular Research aims to be the most trusted supplier of independent, trusted, single-source research on small-to-micro cap companies to the small-to-medium sized Hedge Fund manager. Singular will provide quarterly updates for 30 to 60 companies and make recommendations. Singular's goal is to provide initiation reports and quarterly updates for approximately 50 micro to small cap companies. Singular's independent analysts have no financial interest in the stocks they cover. Analysts are compensated based on the accuracy of their research calls not through trading commissions or potential deal flow. Singular's coverage list performance since inception,
August 2004, is positive 153.59% through
December 2011, compared to 13.88% for the S&P 500. For more information about Singular Research, visit
For more information about the conference, please contact:
Robert Maltbie, CFA
email@example.comAbout Bacterin International Holdings
Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.